Concepedia

Najat Bouchkouj

NB

Statistics

Publications

6

Citations

364

H-Index

6

Active since

2007

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Biologics Evaluation and Research

Najat Bouchkouj is an author at United States Food and Drug Administration specializing in oncology, cancer immunotherapy, and medicine.

Publications per year

2007–2022

6

Publications

6

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro et al. · Clinical Cancer Research · 2018 · 225 citations

Medicine, Oncology, Pharmacotherapy +15

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Najat Bouchkouj, Xue Lin, Xiaofei Wang et al. · The Oncologist · 2022 · 49 citations · Full text

Medicine, Hematology, Oncology +16

Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective

Meena N. Murugappan, Bellinda L. King‐Kallimanis, Gregory H. Reaman et al. · JNCI Journal of the National Cancer Institute · 2021 · 36 citations · Full text

Pharmacy, Child Health, Outcomes Research +16

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

Najat Bouchkouj, Megan Zimmerman, Yvette L. Kasamon et al. · The Oncologist · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16

A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy

Brynn B. Duncan, Steven L. Highfill, Haiying Qin et al. · Journal of Immunotherapy · 2013 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 6